Lone Star Bio

Found 13,418 articles

• Salarius Pharmaceuticals Announces Dr. Daniela Santiesteban to Participate in Panel Discussion on Targeted Cancer Therapies During Virtual NobleCon17 Investor Conference

  1/15/2021

  Salarius Pharmaceuticals, Inc. announced that Daniela Y. Santiesteban, Ph.D., Director of Research and Business Development at Salarius Pharmaceuticals, has been invited to participate in a panel discussion during Noble Capital Markets’ 17th Annual Small & Microcap Investor Conference.

• Sharps Compliance Announces Second Quarter Fiscal 2021 Conference Call and Webcast

  1/14/2021

  Sharps Compliance Corp. announced that it will release its second quarter 2021 results for the period ended December 31, 2020, before the opening of the financial markets on Thursday, January 28, 2021.

• Fuse Medical, Inc. Enters Into Marketing Agreement With CarePICS Telehealth

  1/14/2021

  Fuse Medical, Inc. (OTCPINK: FZMD) (“Fuse” or the “Company”) an emerging manufacturer and distributor of innovative medical devices for the orthopedic and spine marketplace, announced today an agreement with CarePICS, the latest resource addition to Fuse’s comprehensive portfolio and biologics product offerings for wound care.

• Lexicon Pharmaceuticals Provides Regulatory Update on Sotagliflozin in Heart Failure

  1/14/2021

  Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today that it has received U.S. Food and Drug Administration (FDA) regulatory feedback that the results of its SOLOIST and SCORED Phase 3 clinical studies can support a new drug application (NDA) submission for an indication to reduce the risk of cardiovascular death, hospitalization for heart failure,

• Lantern Pharma Announces Pricing of $60 Million Public Offering

  1/14/2021

  Lantern Pharma announced the pricing of a public offering of 4,285,715 shares of its common stock at a public offering price of $14.00 per share, for gross proceeds of $60 million, before deducting underwriting discounts and offering expenses.

• Genprex to Present at NobleCon17 on January 19

  1/14/2021

  Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that the Company will present at the NobleCon17, Noble Capital Markets’ Annual Investor Conference, taking place virtually January 19-20.

• Genprex Achieves Major Manufacturing Milestone for REQORSA™ Immunogene Therapy for Upcoming Trials to Treat Non-Small Cell Lung Cancer

  1/13/2021

  Genprex, Inc. (“Genprex” or the “Company”) (Nasdaq: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, announced today that it has met all specifications and passed all of the final release tests for its first scaled-up clinical-grade manufacturing run of REQORSA™ immunogene therapy,

• Signify Health's Biopharmaceutical Clinical and Caregiver Support Services Remove Barriers to Treatment Associated with Complex Drug Therapies

  1/13/2021

  ignify Health, a leading healthcare platform leveraging advanced analytics, technology and nationwide healthcare networks to create and power value-based programs, is offering a suite of Clinical Support Services and Caregiver Support Services to reduce clinical and social barriers to therapy initiation and adherence.

• Marker Therapeutics Announces Completion of New Manufacturing Facility to Support Clinical Development of MultiTAA-Specific T Cell Therapy Product Candidates

  1/13/2021

  Marker Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced that it has completed the construction and qualification of its cGMP manufacturing facility in Houston, TX, located near the George Bush Intercontinental Airport

• Castle Biosciences Announces Preliminary Fourth Quarter and Full-Year 2020 Results

  1/13/2021

  Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced certain unaudited preliminary performance results for the fourth quarter and full-year 2020.

• Taysha Gene Therapies and UT Southwestern Medical Center Launch Innovation Fund to Accelerate Advancement of AAV Gene Therapies for Monogenic Diseases of the Central Nervous System

  1/13/2021

  Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS) in both rare and large patient populations, and UT Southwestern Medical Center (UTSW) today announced the launch of an innovation fund

• Parexel and Signify Health Collaborating to Develop New Solutions to Promote Access and Inclusion in Clinical Trials

  1/13/2021

  Parexel and Signify Health today announced a strategic collaboration to provide customers with new solutions to enable access to a more diverse and traditionally underrepresented population for their clinical trials.

• HealthTronics Names Bill Linder New Chief Executive Officer

  1/13/2021

  HealthTronics, an Austin-based provider of integrated, mobilized medical technologies and services, has named Bill Linder its new Chief Executive Officer.

• UroGen Pharma and MD Anderson Announce Strategic Research Collaboration to Advance Investigational Treatment for High-Grade Bladder Cancer

  1/13/2021

  UroGen Pharma Ltd. (Nasdaq: URGN), today announced a strategic three-year collaboration agreement to advance combinatorial intravesical immunotherapy, which is delivered directly into the bladder, for the treatment of high-grade non-muscle invasive bladder cancer

• AuraVax Therapeutics Enters into Exclusive License Agreement with Massachusetts General Hospital for Intranasal Vaccine and Therapeutics Platform

  1/13/2021

  AuraVax Therapeutics Inc. (www.auravax.com), a biotech company developing novel intranasal vaccines and therapies to help patients defeat debilitating diseases, including COVID-19, today announced it has entered into an exclusive license agreement with Massachusetts General Hospital (MGH) covering certain intellectual property and technology rights regarding compositions and discoveries of liposomal STING agonists

• ESSA Pharma Announces Clinical Collaboration with Janssen to Evaluate EPI-7386 Combination for Patients with Metastatic Castration-Resistant Prostate Cancer

  1/13/2021

  ESSA Pharma Inc. (Nasdaq: EPIX) ("ESSA" or the "Company"), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that the Company has entered into a clinical collaboration and supply agreement with Janssen Research & Development, LLC (Janssen) to evaluate ESSA's first-in-class N-terminal domain androgen receptor inhibitor,

• Salarius Pharmaceuticals Receives Second Installment of $1.7 Million in Payments from the Cancer Prevention and Research Institute of Texas

  1/13/2021

  Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric cancers, solid tumors, and other cancers, today announced the receipt of a $0.9 million payment as the second installment of $1.7 million in scheduled payments to Salarius under its contract with the Cancer Prevention and Research Institute of Texas (CPRIT)

• Luminex Corporation to Present at 39th Annual J.P. Morgan Healthcare Conference

  1/13/2021

  As previously announced, Luminex Corporation (Nasdaq: LMNX) will present at the 39th Annual J.P. Morgan Healthcare Conference, to be held virtually today, January 13, 2021 at 3:30 p.m. Central Time

• 

  2021 Biopharma Update on the Novel Coronavirus: January 12

  1/12/2021

  Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for January 12, 2021.

• Orthofix Announces Preliminary 2020 Fourth Quarter and Full Year Net Sales Results

  1/12/2021

  Orthofix Medical Inc. (NASDAQ:OFIX) today announced preliminary unaudited fourth quarter 2020 net sales of approximately $118 million, a decrease of 3% on a reported basis and 4% on a constant currency basis.